Seon Hee SHIN

Dr. Seon Hee SHIN

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2012 in BMC Medicine
Verified
Journal Article
Open access
PDF file
MCMin-Kyeong Cha
Min-Kyeong Cha
DLDo-Kyung Lee
Do-Kyung Lee
HAHyang-Mi An
Hyang-Mi An
SLSi-Won Lee
Si-Won Lee
SSSeon Hee SHIN
Seon Hee SHIN
NHNam-Joo Ha
Nam-Joo Ha
Background: Probiotic lactic acid bacteria (LAB) support a functional and balanced immune system, and contribute to immune modulatory effects in combatting microbial pathogens, including viruses. Most cervical cancers are associated with anogenital region infection with high-risk (HR) human papillomavirus (HPV). In this study, we analyzed the antiviral activity ofBifidobacterium adolescentisSPM1005-A in the SiHa cervical cancer cell line expressing HPV type 16.Methods: We assessed the cellular toxicity ofB. adolescentisSPM1005-A in SiHa cells by the Trypan blue dye exclusion assay. Cells (3.6 × 105) in culture plates with or withoutB. adolescentisSPM1005-A in the same type of medium, were incubated with HPV type 16 at a concentration of 5.1 × 107cfu/ml. For antiviral analysis, we performed quantitative real-time PCR (qRT-PCR) for E6 and E7 oncogene expressions and observed protein levels by immunoblotting.Results: The qRT-PCR results showed that E6 and E7 mRNA levels decreased simultaneously. Western blot analysis revealed that the E6 protein expression slightly decreased after 24 and 48 h, but the level of E7 protein expression appear unaffected compared with that in the control. Decreased HPV16 E6 and E7 mRNA transcript and protein levels were not associated with cell morphology or significant cytotoxic effects.Conclusions: This study showed thatB. adolescentisSPM1005-A had antiviral activity through suppression E6 and E7 oncogene expression. The results suggest thatB. adolescentisSPM1005-A could be potential applications of HPV-associated cervical cancer prevention.

21 April 2023 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
EJEun Ju Jung
Eun Ju Jung
SLSu Kyung Lee
Su Kyung Lee
SSSeon Hee SHIN
Seon Hee SHIN
JKJin Soo Kim
Jin Soo Kim
HWHeungjeong Woo
Heungjeong Woo
HKHyun Soo Kim
Hyun Soo Kim
Eun Ju Jung, M.D., Ph.D., Su Kyung Lee, M.S., Seon Hee Shin, M.D., Ph.D., Jin Soo Kim, M.D., Ph.D., Heungjeong Woo, M.D., Ph.D., Eun-Jung Cho, M.D., Ph.D., Jungwon Hyun, M.D., Ph.D., Jae-Seok Kim, M.D., Ph.D., and Hyun Soo Kim, M.D., Ph.D.. Ann Lab Med 2023;43:434-42. https://doi.org/10.3343/alm.2023.43.5.434

3 July 2018 in Gut Pathogens
Verified
Journal Article
Open access
PDF file
SLSu-Kyung Lee
Su-Kyung Lee
SCSeoheui Choi
Seoheui Choi
SSSeon Hee SHIN
Seon Hee SHIN
ELEun Jin Lee
Eun Jin Lee
JHJungwon Hyun
Jungwon Hyun
HKHyun Soo Kim
Hyun Soo Kim
Rotaviruses are the major causes of pediatric gastroenteritis worldwide. The genotypic distribution of rotavirus strains shows temporal and geographical fluctuations, and knowledge of the molecular epidemiology of rotaviruses is important for the development of vaccines and diagnostic reagents. We investigated VP4 and VP7 capsid genotypes of rotaviruses isolated from 211 stool specimens collected from Korean neonates in a neonatal intensive care unit from September 2017 to March 2018. Of 211 stool specimens, 15 specimens (7.1%) were rotavirus-positive. Eleven specimens (73.3%) were G8P[6] type and 4 (26.7%) were G4P[6] type. Sequence analysis revealed that all G8 sequences in this study showed the highest nucleotide identity to G8 sequences of G8P[8] rotavirus strains isolated in Vietnam in 2014, and P[6] gene sequences showed the highest nucleotide identity to P[6] sequences of G4P[6] strains detected in Korea in 2012. Only one amino acid difference in VP7 was found in 3 of the 11 G8P[6] strains in this study, but multiple amino acid substitutions in VP7 were detected between these G8P[6] strains and the commonly used vaccine strains. This study showed that rotavirus G8P[6] strains were firstly detected at high frequency in Korean neonates from September 2017 to March 2018. These new rotavirus G8P[6] strains were estimated to be derived from reassortment events between the G8 of G8P[8] strains in Asian region and the P[6] of G4[6] in Korea. Whether the emergence of this unusual G8P[6] strain reflects continuous prevalence or transient occurrence will require continuous monitoring of rotavirus epidemiology.

1 March 2021 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
SLSu-Kyung Lee
Su-Kyung Lee
SOSu Jin Oh
Su Jin Oh
SCSeoheui Choi
Seoheui Choi
SCSoo-Han Choi
Soo-Han Choi
SSSeon Hee SHIN
Seon Hee SHIN
HKHyun Soo Kim
Hyun Soo Kim
Su-Kyung Lee, M.S., Su Jin Oh, M.S., Seoheui Choi, M.D., Soo Han Choi, M.D., Seon-Hee Shin, M.D., Eun Jin Lee, M.D., Eun-Jung Cho, M.D., Jungwon Hyun, M.D., Hyun Soo Kim, M.D.. Ann Lab Med 2021;41:181-9. https://doi.org/10.3343/alm.2021.41.2.181

1 January 2008 in Korean Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
SSSeon Hee SHIN
Seon Hee SHIN

26 April 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
BKByung Ok Kwak
Byung Ok Kwak
SMSang Hyuk Ma
Sang Hyuk Ma
SPSu Eun Park
Su Eun Park
SSSeon Hee SHIN
Seon Hee SHIN
KCKyung Min Choi
Kyung Min Choi
DKDong Hyun Kim
Dong Hyun Kim
The enhanced inactivated poliovirus vaccine was first introduced in 2002, and several inactivated poliovirus vaccines are licensed in Korea. Reliable data by a prospective study on the immunogenicity and safety of the inactivated poliovirus vaccines in Korean infants are required. Normal healthy infants aged 6–12 weeks received three doses of the vaccine (IPVAX™, Imovax Polio™ or Poliorix™) in intervals of 2 months. Neutralizing antibody (NTAb) titers were measured before and 4–6 weeks after three-dose primary vaccination. Immunogenicity was evaluated by seroconversion rates and geometric mean titers obtained by analyzing NTAb titers. Local and systemic adverse events were recorded during 7 days after each vaccination. A total of 150 infants were included: 40 in IPVAX™, 52 in Imovax Polio™, and 58 in Poliorix™. The seroconversion rates for the group vaccinated with IPVAX™ were 100% in types 1, 2 and 3, while those of Imovax Polio™ were 98.1%, 96.2%, 96.2% and those of Poliorix™ were 98.3%, 100%, 100%, respectively. In all groups, injection site redness and irritability were the most common local and systemic adverse events. Neither serious adverse events nor adverse events above grade 2 were reported throughout the study. The currently used inactivated poliovirus vaccines was demonstrated to be safe and immunogenic in healthy Korean infants.